151 related articles for article (PubMed ID: 37162620)
21. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
[TBL] [Abstract][Full Text] [Related]
22. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
[TBL] [Abstract][Full Text] [Related]
23. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
25. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
[TBL] [Abstract][Full Text] [Related]
26. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164
[TBL] [Abstract][Full Text] [Related]
27. Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma.
Buck SAJ; de Bruijn P; Ghobadi-Moghaddam-Helmantel IM; Lam MH; de Wit R; Koolen SLW; Mathijssen RHJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jun; 1225():123752. PubMed ID: 37269569
[TBL] [Abstract][Full Text] [Related]
28. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
Huang L; Edwards SR; Smith MT
Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361
[TBL] [Abstract][Full Text] [Related]
30. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
[TBL] [Abstract][Full Text] [Related]
31. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
[TBL] [Abstract][Full Text] [Related]
32. Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
Rytkönen J; Ranta VP; Kokki M; Kokki H; Hautajärvi H; Rinne V; Heikkinen AT
Biopharm Drug Dispos; 2020 Feb; 41(1-2):72-88. PubMed ID: 31925778
[TBL] [Abstract][Full Text] [Related]
33. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
[TBL] [Abstract][Full Text] [Related]
34. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
Chan S; Edwards SR; Wyse BD; Smith MT
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
[TBL] [Abstract][Full Text] [Related]
35. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.
Grönlund J; Saari TI; Hagelberg N; Neuvonen PJ; Olkkola KT; Laine K
Antimicrob Agents Chemother; 2011 Mar; 55(3):1063-7. PubMed ID: 21173180
[TBL] [Abstract][Full Text] [Related]
36. A preliminary study of hydrocodone and hydromorphone to oxycodone ratios for distinguishing impurities from independent opioid use.
Choucair I; Villalba CF; Vera MA; Cassella-Mclane G; Durant TJS; El-Khoury JM
Clin Biochem; 2023 Feb; 112():6-10. PubMed ID: 36535386
[TBL] [Abstract][Full Text] [Related]
37. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer.
Hori A; Sahashi H; Sano S; Matsumiya E; Ariga M; Asano A; Soda M; Goto C; Mizui T; Komeda H; Kitaichi K
Anticancer Res; 2020 Dec; 40(12):7101-7108. PubMed ID: 33288609
[TBL] [Abstract][Full Text] [Related]
40. Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites.
French D; Wu A; Lynch K
Bioanalysis; 2011 Dec; 3(23):2603-12. PubMed ID: 22136049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
